However, since TNBC represents a challenge for clinicians due to its poorer prognosis, lack of targeted therapies and high mortality in comparison to other breast cancer subtypes, we decided to examine the effects of Pak and CaMKII combined inhibition in the survival of TNBC cells. The gene discussed is CAMK2G; the disease is breast carcinoma.